Header Logo

VICTOR RIVERA

TitleDistinguished Emeritus Professor
InstitutionBaylor College of Medicine
DepartmentDepartment of Neurology
Address7200 CAMBRIDGE
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Ramirez DA, Gracia F, Jimenez AJD, Alvarez PM, Candelario AE, Castro-Escobar R, Rivas AIP, Diaz de la Fe A, Cama?o DRD, Sotelo OAD, Valle LAG, Juarez GMAG, Torres EL, Vindas AP, Rivera LIP, Sanchez NER, Salinas LCR, Pujols BS, Santana SBV, Angeles IZ, Pena JA, Rivera VM. Central American and Caribbean consensus for the treatment of MS, NMOSD, and MOGAD. Mult Scler Relat Disord. 2025 Mar; 95:106334. PMID: 39954489.
      Citations:    Fields:    Translation:Humans
    2. Rivera VM. Advances in Multiple Sclerosis. Biomedicines. 2025 Jan 22; 13(2). PMID: 40002680; PMCID: PMC11852374.
      Citations:    
    3. Alonso R, Rivera V, Carnero Contentti EG, Hamuy Diaz de Bedoya VF, Ciampi E, Silva B, Zuluaga M, Becker J, Rojas JI, Gracia F, Zarco L, Tkachuk V, Molt F, Soto I, Fernandez Calderon R, L?pez P, Patrucco L, Trevi?o-Frenk I, Sato D, Ramirez D, Navas C, Fujihara K, Galleguillos L. Recommendations on NMOSD treatment in Latin America: Utilizing consensus-based RAND/UCLA methodology. Mult Scler Relat Disord. 2025 Feb; 94:106244. PMID: 39823690.
      Citations: 2     Fields:    Translation:Humans
    4. Amezcua L, Rotstein D, Shirani A, Ciccarelli O, Ontaneda D, Magyari M, Rivera V, Kimbrough D, Dobson R, Taylor B, Williams M, Marrie RA, Banwell B, Hemmer B, Newsome SD, Cohen JA, Solomon AJ, Royal W. Differential diagnosis of suspected multiple sclerosis: considerations in people from minority ethnic and racial backgrounds in North America, northern Europe, and Australasia. Lancet Neurol. 2024 Oct; 23(10):1050-1062. PMID: 39304244.
      Citations: 3     Fields:    Translation:Humans
    5. Preston WA, Collins ML, G?nen M, Murtha T, Rivera V, Lamm R, Schafer M, Yarmohammadi H, Covey A, Brody LA, Topper S, Nevler A, Lavu H, Yeo CJ, Balachandran VP, Drebin JA, Soares KC, Wei AC, Kingham TP, D'Angelica MI, Jarnagin WR. Hemorrhage Sites and Mitigation Strategies After Pancreaticoduodenectomy. JAMA Surg. 2024 Aug 01; 159(8):891-899. PMID: 38776076; PMCID: PMC11112495.
      Citations:    
    6. Gracia F, Ram?rez Navarro DA, Ram?rez S?nchez NE, Weiser R, Parajeles-Vindas A, Portillo Rivera LI, Torres EL, Garc?a Valle LA, Sanabria-Castro A, Abd?n L?pez C, Araujo P, Ayerdis Zamora MJ, Balmaceda-Meza A, Benzadon Cohen A, Candelario Cueto A, Castillo D, Castro-Escobar R, Corea Urbina KZ, de Pe?a Rivas A, Sotelo OD, Enamorado Claros T, Giroud Ben?tez JL, Gracia K, Larreategui M, Mart?nez Cerrato JA, Medina B?ez JP, Menjivar Samayoa CE, Miranda-Loria G, Monterrey-Alvarez P, Morales Arguello LA, Ortiz M, P?rez Baldioceda CD, Pinilla Aguilar L, Salinas LCR, Rodr?guez-Moreno V, Rojas-Chaves S, Rom?n-Garita N, Santos Pujols B, Valderrama C, Van Sijtveld I, Zabala Angeles I, Rivera VM, Armien B. Multiple sclerosis in Central America and Caribbean countries: frequency and clinical characterization of an emergent disease. Front Epidemiol. 2024; 4:1368675. PMID: 38952354; PMCID: PMC11216161.
      Citations:    
    7. Rojas JI, Gracia F, Parciak T, Alonso R, Becker J, Trevi?o-Frenk I, Alonso-Serena M, Giunta D, Abad P, Carnero-Contentti E, Carr? A, Correa-D?az EP, Correale J, Cristiano E, Flores J, Fruns M, Galleguillos L, Garcea O, Hamuy F, Lana-Peixoto M, Navas C, Pappais-Alvarenga R, Patrucco L, Rivera V, Tenembaum S, Ysrraelit MC, Peeters LM. [Core data set for real world data in multiple sclerosis: customization for latin america from a global task force recommendation]. Rev Neurol. 2024 04 01; 78(7):185-197. PMID: 38502167; PMCID: PMC11407452.
      Citations:    Fields:    Translation:Humans
    8. Rivera VM. Neuromyelitis Optica Spectrum Disorder: Redefining an Old Disease. Present and Future Challenges. J Integr Neurosci. 2023 10 18; 22(6):139. PMID: 38176944.
      Citations:    Fields:    Translation:Humans
    9. Liu C, Leighow SM, McIlroy K, Lu M, Dennis KA, Abello K, Brown DJ, Moore CJ, Shah A, Inam H, Rivera VM, Pritchard JR. Excessive concentrations of kinase inhibitors in translational studies impede effective drug repurposing. Cell Rep Med. 2023 10 17; 4(10):101227. PMID: 37852183; PMCID: PMC10591048.
      Citations:    Fields:    Translation:Humans
    10. Avila M, Tan Y, Hernandez R, Zuberi H, Rivera VM. Correction to: Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: Onset Following Acute COVID-19 Infection, a Case Series. Neurol Ther. 2023 Apr; 12(2):701. PMID: 36821074; PMCID: PMC9948788.
      Citations:    
    11. Avila M, Hernandez R, Zuberi H, Rivera VM, Tan Y. Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: Onset Following Acute COVID-19 Infection, a Case Series. Neurol Ther. 2023 Feb; 12(1):319-327. PMID: 36399224; PMCID: PMC9672646.
      Citations: 3     
    12. George S, von Mehren M, Fletcher JA, Sun J, Zhang S, Pritchard JR, Hodgson JG, Kerstein D, Rivera VM, Haluska FG, Heinrich MC. Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers. Clin Cancer Res. 2022 04 01; 28(7):1268-1276. PMID: 35091442; PMCID: PMC9531534.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    13. Parajeles-Vindas A, Weiser R, Santos B, Candelario A, Benzadon A, Araujo P, Larreategui M, Monterrey-Alvarez P, Sanabria-Castro A, Miranda-Loria G, Rivera LIP, Leal IO, Thompson A, Zepeda C, Van Sijtveld I, Rivera VM, Gracia F, Ram?rez D, D?az A, D?az de la F? A, S?nchez NER, Escobar RC, Valle LAG, Valderrama C, Carrillo G, Gracia K, V?zquez-C?spedes J, Carazo-C?spedes K, Balmaceda-Meza A, Salinas LCR, Torres EL, Pereira DE, L?pez CA, Valse EAC, Urbina KZC, Urrutia MA, Armien B. Neuromyelitis Optica Spectrum Disorder in Central America and the Caribbean: A Multinational Clinical Characterization Study. Neurol Int. 2022 Mar 17; 14(1):284-293. PMID: 35324579; PMCID: PMC8952282.
      Citations:    
    14. Amezcua L, Rivera VM, Vazquez TC, Baezconde-Garbanati L, Langer-Gould A. Health Disparities, Inequities, and Social Determinants of Health in Multiple Sclerosis and Related Disorders in the US: A Review. JAMA Neurol. 2021 12 01; 78(12):1515-1524. PMID: 34605866.
      Citations:    
    15. Rivera VM. Editorial of Special Issue "Multiple Sclerosis: Diagnosis and Treatment II". Biomedicines. 2021 Nov 03; 9(11). PMID: 34829833; PMCID: PMC8615709.
      Citations:    
    16. Rivera VM, Hamuy F, Rivas V, Gracia F, Bichuetti DB, Marques VD, Soto A, Bertado B, Ramirez DA, Ciampi E, Lana-Peixoto MA, Zarco L, Becker J, Lopez E, Carnero Contentti E, Diaz A, Playas G, Rojas E, Sato D, Correale J, Barboza A, Monterrey P, Candelario A, Tavolini DR, Raggio JV, Ramirez NE, Skromne E, Portillo LL, Canabal AP, Weiser R, Sirias V, Quiroz JCD, Garcia LA, Abad-Herrera P, Rojas JI, Villa AM, Frenk IT, Galleguillos L, Qui?ones J, Capar?-Zamalloa C, Rodr?guez E, Sinay V, Armas E, Benzad?n A, Correa-Diaz EP, Fleitas CV, Molina O, Soto I, C?spedes JV, Parajeles A, Pujol BS, Diaz de la Fe A, Alonso R, Bola?a C, Guzman MK, Carr? A, Gamarra OG, Rodriguez LC, Ordo?ez L, Calder?n RF, Cornejo EA, Hern?ndez M, Cede?o CO, Mart?nez J. Status of the neuromyelitis optica spectrum disorder in Latin America. Mult Scler Relat Disord. 2021 Aug; 53:103083. PMID: 34171682.
      Citations: 2     Fields:    Translation:Humans
    17. Abad P, Becker J, Carra A, Correale J, Diaz AJ, Fruns M, Giachello SM, Gracia F, Hamuy VF, Henestroza PR, Navas C, Rivera VM, Ysrraelit MC, Alonso Serena M, on behalf research priorities LACTRIMS working group, Rojas JI, Carnero Contentti E, Aguayo A, Alonso R, Bauer J, Bustos AK, Carcamo CA, Correa Diaz EP, Cristiano E, Fernandez Liguori N, Flores J, Garcea O, Godoy MD, Navarra JA, Patrucco L, Perez Bruno M, Prato AS, Rosa Martinez AR, Vanotti S, Vazquez M, Vizcarra D. Research priorities in multiple sclerosis in Latin America: A multi-stakeholder call to action to improve patients care: Research priorities in MS in LATAM. Mult Scler Relat Disord. 2021 Aug; 53:103038. PMID: 34090128.
      Citations:    Fields:    Translation:HumansCells
    18. Rivera VM, Gracia F, D?az A. [Therapeutic attitudes towards multiple sclerosis in Central America and the Caribbean facing the SARS-CoV-2 pandemia]. Neurologia (Engl Ed). 2020 Nov - Dec; 35(9):705-706. PMID: 32893070; PMCID: PMC7386366.
      Citations:    Fields:    Translation:HumansCellsPHPublic Health
    19. Short NJ, Kantarjian H, Kanagal-Shamanna R, Sasaki K, Ravandi F, Cortes J, Konopleva M, Issa GC, Kornblau SM, Garcia-Manero G, Garris R, Higgins J, Pratt G, Williams LN, Valentine CC, Rivera VM, Pritchard J, Salk JJ, Radich J, Jabbour E. Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL. Blood Cancer J. 2020 05 26; 10(5):61. PMID: 32457305; PMCID: PMC7250857.
      Citations: 3     Fields:    Translation:HumansCells
    20. Fisher KS, Cuascut FX, Rivera VM, Hutton GJ. Current Advances in Pediatric Onset Multiple Sclerosis. Biomedicines. 2020 Mar 28; 8(4). PMID: 32231060; PMCID: PMC7235875.
      Citations: 5     
    21. Rivera VM. Biosimilar Drugs for Multiple Sclerosis: An Unmet International Need or a Regulatory Risk? Neurol Ther. 2019 Dec; 8(2):177-184. PMID: 31313222; PMCID: PMC6858917.
      Citations: 1     
    22. Castillo-Mart?nez D, Rivera V, Mouneu-Ornelas N, Mart?nez-Mart?nez LA, Jim?nez-Rojas V, M?rquez-Velasco R, Amezcua-Guerra LM. Levels of anti-M?llerian hormone in premenopausal women with the antiphospholipid syndrome and its association with the risk of clinical complications. Lupus. 2019 Mar; 28(3):427-431. PMID: 30717622.
      Citations:    Fields:    Translation:Humans
    23. Rivera VM. Multiple Sclerosis: A Global Concern with Multiple Challenges in an Era of Advanced Therapeutic Complex Molecules and Biological Medicines. Biomedicines. 2018 Nov 30; 6(4). PMID: 30513578; PMCID: PMC6316848.
      Citations: 4     
    24. Reif LK, Rivera V, Bertrand R, Rouzier V, Kutscher E, Walsh K, Charles B, Pape JW, Fitzgerald DW, Koenig SP, McNairy ML. Outcomes across the tuberculosis care continuum among adolescents in Haiti. Public Health Action. 2018 Sep 21; 8(3):103-109. PMID: 30271725; PMCID: PMC6147066.
      Citations:    
    25. Schmitt MW, Pritchard JR, Leighow SM, Aminov BI, Beppu L, Kim DS, Hodgson JG, Rivera VM, Loeb LA, Radich JP. Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias. Clin Cancer Res. 2018 11 01; 24(21):5321-5334. PMID: 30042204; PMCID: PMC6214777.
      Citations: 7     Fields:    Translation:HumansCells
    26. Gozgit JM, Chen TH, Song Y, Wardwell S, Wang F, Cai J, Li H, Edgren H, Rivera VM, Pritchard J. RET fusions observed in lung and colorectal cancers are sensitive to ponatinib. Oncotarget. 2018 Jul 03; 9(51):29654-29664. PMID: 30038711; PMCID: PMC6049858.
      Citations: 10     Fields:    
    27. Cortes JE, Kim DW, Pinilla-Ibarz J, Paquette R, Chuah C, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Baccarani M, Gambacorti-Passerini C, Lustgarten S, Rivera VM, Haluska FG, Deininger MW, Hochhaus A, Hughes TP, Shah NP, Kantarjian HM, le Coutre PD, Nicolini FE, Rea D, M?ller MC, Guilhot F. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018 07 26; 132(4):393-404. PMID: 29567798; PMCID: PMC6071555.
      Citations: 119     Fields:    Translation:HumansCellsCTClinical Trials
    28. Rivera VM. Multiple sclerosis as a universal disease and the challenges to immigrants in high prevalence countries. Eur J Neurol. 2018 04; 25(4):612-613. PMID: 29341368.
      Citations:    Fields:    Translation:Humans
    29. Strickler AS, Palma J, Charris R, Candia T, Grez M, Gonz?lez B, King A, Rivera V. Contribution of the use of basic telemedicine tools to the care of children and adolescents with juvenile idiopathic arthritis at the Puerto Montt Hospital, Chile. Rev Chil Pediatr. 2018 Feb; 89(1):59-66. PMID: 29664504.
      Citations:    
    30. Rivera VM. Multiple Sclerosis in Latin Americans: Genetic Aspects. Curr Neurol Neurosci Rep. 2017 Aug; 17(8):57. PMID: 28639238.
      Citations: 3     Fields:    Translation:Humans
    31. Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, Shaw AT, Weiss GJ, Tugnait M, Narasimhan NI, Dorer DJ, Kerstein D, Rivera VM, Clackson T, Haluska FG, Camidge DR. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol. 2016 Dec; 17(12):1683-1696. PMID: 27836716.
      Citations: 113     Fields:    Translation:HumansCTClinical Trials
    32. Zhang S, Anjum R, Squillace R, Nadworny S, Zhou T, Keats J, Ning Y, Wardwell SD, Miller D, Song Y, Eichinger L, Moran L, Huang WS, Liu S, Zou D, Wang Y, Mohemmad Q, Jang HG, Ye E, Narasimhan N, Wang F, Miret J, Zhu X, Clackson T, Dalgarno D, Shakespeare WC, Rivera VM. The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models. Clin Cancer Res. 2016 Nov 15; 22(22):5527-5538. PMID: 27780853.
      Citations: 103     Fields:    Translation:HumansCells
    33. Parra-Bernal MC, Rivera-Olmos VM. [Cannabis: Effects in the Central Nervous System. Therapeutic, societal and legal consequences]. Rev Med Inst Mex Seguro Soc. 2016 Sep-Oct; 54(5):626-34. PMID: 27428345.
      Citations: 3     Fields:    Translation:HumansAnimals
    34. Siaw JT, Wan H, Pfeifer K, Rivera VM, Guan J, Palmer RH, Hallberg B. Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice. Oncotarget. 2016 May 17; 7(20):29011-22. PMID: 27049722; PMCID: PMC5045374.
      Citations:    
    35. Huang WS, Liu S, Zou D, Thomas M, Wang Y, Zhou T, Romero J, Kohlmann A, Li F, Qi J, Cai L, Dwight TA, Xu Y, Xu R, Dodd R, Toms A, Parillon L, Lu X, Anjum R, Zhang S, Wang F, Keats J, Wardwell SD, Ning Y, Xu Q, Moran LE, Mohemmad QK, Jang HG, Clackson T, Narasimhan NI, Rivera VM, Zhu X, Dalgarno D, Shakespeare WC. Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase. J Med Chem. 2016 05 26; 59(10):4948-64. PMID: 27144831.
      Citations:    
    36. Lipton JH, Chuah C, Rosti G, Simpson D, Clark RE, Stenke L, Andorsky D, Oehler V, Lustgarten S, Rivera VM, Clackson T, Haluska FG, Baccarani M, Cortes JE, Hughes T, Kantarjian HM, Shah NP, Talpaz M, Deininger MW, EPIC investigators, Guerci-Bresler A, Assouline S, Etienne G, Nicolini FE, le Coutre P, Guilhot F, Hochhaus A. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2016 05; 17(5):612-21. PMID: 27083332.
      Citations: 79     Fields:    Translation:HumansCellsCTClinical Trials
    37. Parker WT, Yeung DT, Yeoman AL, Altamura HK, Jamison BA, Field CR, Hodgson JG, Lustgarten S, Rivera VM, Hughes TP, Branford S. The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib. Blood. 2016 Apr 14; 127(15):1870-80. PMID: 26773037; PMCID: PMC4832506.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    38. Deininger MW, Hodgson JG, Shah NP, Cortes JE, Kim DW, Nicolini FE, Talpaz M, Baccarani M, Li J, Parker WT, Lustgarten S, Clackson T, Haluska FG, Guilhot F, Kantarjian HM, Soverini S, Hughes TP, Rivera VM, Branford S, M?ller MC, Hochhaus A. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood. 2016 Feb 11; 127(6):703-12. PMID: 26603839; PMCID: PMC4760131.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    39. Baker T, Nerle S, Pritchard J, Zhao B, Rivera VM, Garner A, Gonzalvez F. Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors. Oncotarget. 2015 Oct 20; 6(32):32646-55. PMID: 26360609; PMCID: PMC4741719.
      Citations: 33     Fields:    Translation:HumansCells
    40. Garner AP, Gozgit JM, Anjum R, Vodala S, Schrock A, Zhou T, Serrano C, Eilers G, Zhu M, Ketzer J, Wardwell S, Ning Y, Song Y, Kohlmann A, Wang F, Clackson T, Heinrich MC, Fletcher JA, Bauer S, Rivera VM. Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients. Clin Cancer Res. 2014 Nov 15; 20(22):5745-5755. PMID: 25239608; PMCID: PMC4233175.
      Citations: 64     Fields:    Translation:HumansAnimalsCells
    41. Rivera VM, Medina MT, Duron RM, Macias MA. Multiple sclerosis care in Latin America. Neurology. 2014 May 06; 82(18):1660-1. PMID: 24799516; PMCID: PMC4013811.
      Citations: 11     Fields:    Translation:Humans
    42. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H, PACE Investigators, M?ller MC. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013 Nov 07; 369(19):1783-96. PMID: 24180494; PMCID: PMC3886799.
      Citations: 353     Fields:    Translation:HumansCTClinical Trials
    43. Rivera VM, Jeffery DR, Weinstock-Guttman B, Bock D, Dangond F. Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study. BMC Neurol. 2013 Jul 11; 13:80. PMID: 23841877; PMCID: PMC3710498.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    44. Soria-Cedillo IF, Velazquez-Quintana M, Rivera VM, Lemus-Carmona EA, Chiquete E, Mac?as-Islas MA, Baca-Muro VI. Cost of care according to disease-modifying therapy in Mexicans with relapsing-remitting multiple sclerosis. Acta Neurol Belg. 2013 Dec; 113(4):415-20. PMID: 23670405.
      Citations: 3     Fields:    Translation:Humans
    45. Gozgit JM, Squillace RM, Wongchenko MJ, Miller D, Wardwell S, Mohemmad Q, Narasimhan NI, Wang F, Clackson T, Rivera VM. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models. Cancer Chemother Pharmacol. 2013 May; 71(5):1315-23. PMID: 23468082.
      Citations: 28     Fields:    Translation:HumansAnimalsCells
    46. Kohlmann A, Zech SG, Li F, Zhou T, Squillace RM, Commodore L, Greenfield MT, Lu X, Miller DP, Huang WS, Qi J, Thomas RM, Wang Y, Zhang S, Dodd R, Liu S, Xu R, Xu Y, Miret JJ, Rivera V, Clackson T, Shakespeare WC, Zhu X, Dalgarno DC. Fragment growing and linking lead to novel nanomolar lactate dehydrogenase inhibitors. J Med Chem. 2013 Feb 14; 56(3):1023-40. PMID: 23302067.
      Citations:    
    47. Abad P, Nogales-Gaete J, Rivera V, Cristiano E, Hamuy F, Oehninger C, Alvarenga RM, Tenembaum S, Grupo de Estudio de Esclerosis M?ltiple de Latinoam?rica Lactrims. [LACTRIMS consensus document for the pharmacological treatment of the multiple sclerosis and its clinical variants]. Rev Neurol. 2012 Dec 16; 55(12):737-48. PMID: 23233142.
      Citations: 3     Fields:    Translation:Humans
    48. Mita MM, Poplin E, Britten CD, Tap WD, Rubin EH, Scott BB, Berk L, Rivera VM, Loewy JW, Dodion P, Haluska F, Sarantopoulos J, Mita A, Tolcher A. Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma. Ann Oncol. 2013 Apr; 24(4):1104-11. PMID: 23211938.
      Citations: 14     Fields:    Translation:HumansAnimalsCTClinical Trials
    49. Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, O'Hare T, Hu S, Narasimhan NI, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MW, Talpaz M. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012 Nov 29; 367(22):2075-88. PMID: 23190221; PMCID: PMC3777383.
      Citations: 272     Fields:    Translation:HumansCTClinical Trials
    50. Squillace RM, Miller D, Wardwell SD, Wang F, Clackson T, Rivera VM. Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models. Int J Oncol. 2012 Aug; 41(2):425-32. PMID: 22614157; PMCID: PMC3582879.
      Citations:    
    51. Vargas M, Loyola C, Zapata N, Rivera V, Secor G, Bolton M, France A. First Report of Root Rot of Chicory Caused by Phytophthora cryptogea in Chile. Plant Dis. 2012 Apr; 96(4):591. PMID: 30727403.
      Citations:    
    52. Gozgit JM, Wong MJ, Moran L, Wardwell S, Mohemmad QK, Narasimhan NI, Shakespeare WC, Wang F, Clackson T, Rivera VM. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol Cancer Ther. 2012 Mar; 11(3):690-9. PMID: 22238366.
      Citations: 141     Fields:    Translation:HumansAnimalsCells
    53. Berk L, Mita MM, Kreisberg J, Bedrosian CL, Tolcher AW, Clackson T, Rivera VM. Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial. Cancer Chemother Pharmacol. 2012 May; 69(5):1369-77. PMID: 22231376.
      Citations:    
    54. Chawla SP, Staddon AP, Baker LH, Schuetze SM, Tolcher AW, D'Amato GZ, Blay JY, Mita MM, Sankhala KK, Berk L, Rivera VM, Clackson T, Loewy JW, Haluska FG, Demetri GD. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol. 2012 01 01; 30(1):78-84. PMID: 22067397.
      Citations: 101     Fields:    Translation:HumansCTClinical Trials
    55. Zhang S, Wang F, Keats J, Zhu X, Ning Y, Wardwell SD, Moran L, Mohemmad QK, Anjum R, Wang Y, Narasimhan NI, Dalgarno D, Shakespeare WC, Miret JJ, Clackson T, Rivera VM. Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chem Biol Drug Des. 2011 Dec; 78(6):999-1005. PMID: 22034911; PMCID: PMC3265718.
      Citations: 57     Fields:    Translation:HumansCells
    56. Reardon DA, Wen PY, Alfred Yung WK, Berk L, Narasimhan N, Turner CD, Clackson T, Rivera VM, Vogelbaum MA. Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial. Cancer Chemother Pharmacol. 2012 Apr; 69(4):849-60. PMID: 22037923.
      Citations:    
    57. O'Hare T, Zabriskie MS, Eide CA, Agarwal A, Adrian LT, You H, Corbin AS, Yang F, Press RD, Rivera VM, Toplin J, Wong S, Deininger MW, Druker BJ. The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Blood. 2011 Nov 10; 118(19):5250-4. PMID: 21908430; PMCID: PMC3217407.
      Citations: 21     Fields:    Translation:HumansCells
    58. Squillace RM, Miller D, Cookson M, Wardwell SD, Moran L, Clapham D, Wang F, Clackson T, Rivera VM. Antitumor activity of ridaforolimus and potential cell-cycle determinants of sensitivity in sarcoma and endometrial cancer models. Mol Cancer Ther. 2011 Oct; 10(10):1959-68. PMID: 21825008.
      Citations:    
    59. Stosic M, De Jesus P, McCarthy J, Hutton G, Rivera V. Immune thrombocytopenic purpura in a patient with multiple sclerosis treated with natalizumab. Neurology. 2011 Aug 02; 77(5):505-7. PMID: 21775738.
      Citations: 2     Fields:    Translation:Humans
    60. Rivera VM. Tovaxin for multiple sclerosis. Expert Opin Biol Ther. 2011 Jul; 11(7):961-7. PMID: 21563876.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    61. Thomas M, Huang WS, Wen D, Zhu X, Wang Y, Metcalf CA, Liu S, Chen I, Romero J, Zou D, Sundaramoorthi R, Li F, Qi J, Cai L, Zhou T, Commodore L, Xu Q, Keats J, Wang F, Wardwell S, Ning Y, Snodgrass JT, Broudy MI, Russian K, Iuliucci J, Rivera VM, Sawyer TK, Dalgarno DC, Clackson T, Shakespeare WC. Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant. Bioorg Med Chem Lett. 2011 Jun 15; 21(12):3743-8. PMID: 21561767.
      Citations:    
    62. Gozgit JM, Wong MJ, Wardwell S, Tyner JW, Loriaux MM, Mohemmad QK, Narasimhan NI, Shakespeare WC, Wang F, Druker BJ, Clackson T, Rivera VM. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol Cancer Ther. 2011 Jun; 10(6):1028-35. PMID: 21482694; PMCID: PMC3236248.
      Citations: 60     Fields:    Translation:HumansAnimalsCells
    63. Rivera VM, Squillace RM, Miller D, Berk L, Wardwell SD, Ning Y, Pollock R, Narasimhan NI, Iuliucci JD, Wang F, Clackson T. Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens. Mol Cancer Ther. 2011 Jun; 10(6):1059-71. PMID: 21482695.
      Citations:    
    64. Avila-Ornelas J, Avila M, Stosic M, Robles L, Prieto PG, Hutton GJ, Rivera VM. The role of postpartum intravenous corticosteroids in the prevention of relapses in multiple sclerosis. Int J MS Care. 2011; 13(2):91-3. PMID: 24453710; PMCID: PMC3882955.
      Citations: 3     
    65. Uitdehaag B, Constantinescu C, Cornelisse P, Jeffery D, Kappos L, Li D, Sandberg-Wollheim M, Traboulsee A, Verdun E, Rivera V. Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study. Ther Adv Neurol Disord. 2011 Jan; 4(1):3-14. PMID: 21339904; PMCID: PMC3036958.
      Citations: 19     
    66. Zhou T, Commodore L, Huang WS, Wang Y, Thomas M, Keats J, Xu Q, Rivera VM, Shakespeare WC, Clackson T, Dalgarno DC, Zhu X. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des. 2011 Jan; 77(1):1-11. PMID: 21118377.
      Citations: 83     Fields:    Translation:AnimalsCells
    67. Perotti A, Locatelli A, Sessa C, Hess D, Capri G, Maur M, Cerny T, Cresta S, Rojo F, Albanell J, Marsoni S, Corradino I, Berk L, Rivera VM, Haluska F, Gianni L, Vigan? L. Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine. J Clin Oncol. 2010 Oct 20; 28(30):4554-61. PMID: 20855840.
      Citations: 16     Fields:    Translation:HumansCellsCTClinical Trials
    68. García-Gubern C, Bello R, Rivera V, Rocafort A, Colon-Rolon L, Acosta-Tapia H, Garc?a-Gubern C, Bello R. Is the Puerto Rican racer, Alsophis portoricensis, really harmless? A case report series. Wilderness Environ Med. 2010 Dec; 21(4):353-6. PMID: 21168790.
      Citations:    
    69. Huang WS, Metcalf CA, Sundaramoorthi R, Wang Y, Zou D, Thomas RM, Zhu X, Cai L, Wen D, Liu S, Romero J, Qi J, Chen I, Banda G, Lentini SP, Das S, Xu Q, Keats J, Wang F, Wardwell S, Ning Y, Snodgrass JT, Broudy MI, Russian K, Zhou T, Commodore L, Narasimhan NI, Mohemmad QK, Iuliucci J, Rivera VM, Dalgarno DC, Sawyer TK, Clackson T, Shakespeare WC. Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. J Med Chem. 2010 Jun 24; 53(12):4701-19. PMID: 20513156.
      Citations: 90     Fields:    Translation:AnimalsCells
    70. Cohen BA, Rivera VM. PRISMS: the story of a pivotal clinical trial series in multiple sclerosis. Curr Med Res Opin. 2010 Apr; 26(4):827-38. PMID: 20121658.
      Citations: 8     Fields:    Translation:Humans
    71. Rivera VM. The challenge of follow-on biologics for treatment of multiple sclerosis. Neurology. 2010 Mar 09; 74(10):864. PMID: 20211915.
      Citations:    Fields:    Translation:Humans
    72. Sessa C, Tosi D, Albanell J, Hess D, Maur M, Cresta S, Locatelli A, Angst R, Rojo F, Coceani N, Rivera VM, Berk L, Haluska F, Gianni L, Vigan? L. Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel. Ann Oncol. 2010 Jun; 21(6):1315-1322. PMID: 19901013.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    73. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, Ning Y, Keats JA, Wang Y, Sundaramoorthi R, Thomas M, Zhou D, Snodgrass J, Commodore L, Sawyer TK, Dalgarno DC, Deininger MW, Druker BJ, Clackson T. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009 Nov 06; 16(5):401-12. PMID: 19878872; PMCID: PMC2804470.
      Citations: 440     Fields:    Translation:HumansAnimalsCells
    74. Rivera VM. Multiple sclerosis in Latin America: reality and challenge. Neuroepidemiology. 2009; 32(4):294-5. PMID: 19246934.
      Citations: 7     Fields:    Translation:Humans
    75. Hartford CM, Desai AA, Janisch L, Karrison T, Rivera VM, Berk L, Loewy JW, Kindler H, Stadler WM, Knowles HL, Bedrosian C, Ratain MJ. A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res. 2009 Feb 15; 15(4):1428-34. PMID: 19228743; PMCID: PMC3147153.
      Citations: 31     Fields:    Translation:HumansCellsCTClinical Trials
    76. Sabnani I, Zucker MJ, Rosenstein ED, Baran DA, Arroyo LH, Tsang P, Zubair M, Rivera V. A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide. Rheumatology (Oxford). 2009 Jan; 48(1):49-52. PMID: 18815156.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    77. Rizzieri DA, Feldman E, Dipersio JF, Gabrail N, Stock W, Strair R, Rivera VM, Albitar M, Bedrosian CL, Giles FJ. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2008 May 01; 14(9):2756-62. PMID: 18451242.
      Citations: 83     Fields:    Translation:HumansCTClinical Trials
    78. Mita MM, Mita AC, Chu QS, Rowinsky EK, Fetterly GJ, Goldston M, Patnaik A, Mathews L, Ricart AD, Mays T, Knowles H, Rivera VM, Kreisberg J, Bedrosian CL, Tolcher AW. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol. 2008 Jan 20; 26(3):361-7. PMID: 18202410.
      Citations: 91     Fields:    Translation:HumansCTClinical Trials
    79. Nguyen M, Huan-Tu G, Gonzalez-Edick M, Rivera VM, Clackson T, Jooss KU, Harding TC. Rapamycin-regulated control of antiangiogenic tumor therapy following rAAV-mediated gene transfer. Mol Ther. 2007 May; 15(5):912-20. PMID: 17245354.
      Citations:    
    80. Butzkueven H, Chapman J, Cristiano E, Grand'Maison F, Hoffmann M, Izquierdo G, Jolley D, Kappos L, Leist T, Rivera V, Trojano M, Verheul F, Malkowski JP, P?hlau D. MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis. Mult Scler. 2006 Dec; 12(6):769-74. PMID: 17263005.
      Citations: 51     Fields:    Translation:Humans
    81. Skromne E, Rivera VM, Ontaneda D, Ordonez L. Progression of progressive multifocal leukoencephalopathy despite treatment with beta-interferon. Neurology. 2006 Jun 13; 66(11):1787-8; author reply 1787-8. PMID: 16769975.
      Citations: 1     Fields:    Translation:HumansCells
    82. Ordonez L, Skromne E, Ontaneda D, Rivera VM. Multiphasic disseminated encephalomyelitis, systemic lupus erythematosus and antiphospholipid syndrome. Clin Neurol Neurosurg. 2007 Jan; 109(1):102-5. PMID: 16624483.
      Citations: 2     Fields:    Translation:Humans
    83. Rivera VM. Modafinil for the treatment of diminished responsiveness in a patient recovering from brain surgery. Brain Inj. 2005 Aug 20; 19(9):725-7. PMID: 16195186.
      Citations:    Fields:    Translation:Humans
    84. Rivera VM. Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology. 2005 Jun 28; 64(12):2163. PMID: 15985607.
      Citations:    Fields:    Translation:Humans
    85. Cohen BA, Khan O, Jeffery DR, Bashir K, Rizvi SA, Fox EJ, Agius M, Bashir R, Collins TE, Herndon R, Kinkel P, Mikol DD, Picone MA, Rivera V, Tornatore C, Zwibel H. Identifying and treating patients with suboptimal responses. Neurology. 2004 Dec 28; 63(12 Suppl 6):S33-40. PMID: 15623669.
      Citations: 14     Fields:    Translation:Humans
    86. Rivera VM, Gao GP, Grant RL, Schnell MA, Zoltick PW, Rozamus LW, Clackson T, Wilson JM. Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood. 2005 Feb 15; 105(4):1424-30. PMID: 15507527.
      Citations: 104     Fields:    Translation:AnimalsCells
    87. Zang YC, Skinner SM, Robinson RR, Li S, Rivera VM, Hutton GJ, Zhang JZ. Regulation of differentiation and functional properties of monocytes and monocyte-derived dendritic cells by interferon beta in multiple sclerosis. Mult Scler. 2004 Oct; 10(5):499-506. PMID: 15471364.
      Citations: 8     Fields:    Translation:HumansCells
    88. O'Hare T, Pollock R, Stoffregen EP, Keats JA, Abdullah OM, Moseson EM, Rivera VM, Tang H, Metcalf CA, Bohacek RS, Wang Y, Sundaramoorthi R, Shakespeare WC, Dalgarno D, Clackson T, Sawyer TK, Deininger MW, Druker BJ. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood. 2004 Oct 15; 104(8):2532-9. PMID: 15256422.
      Citations: 44     Fields:    Translation:HumansCells
    89. Hong J, Zang YC, Hutton G, Rivera VM, Zhang JZ. Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis. J Neuroimmunol. 2004 Jul; 152(1-2):126-39. PMID: 15223245.
      Citations: 15     Fields:    Translation:HumansCells
    90. Arroyo P, Ortiz Nolasco R, Godoy López M, Garcia Gubern C, Rivera V, Godoy L?pez M. A junctional rhythm with retrograde conduction and bradycardia as a dysrhythmia caused by oral phenytoin toxicity. Bol Asoc Med P R. 2004 May-Aug; 96(3):134-8. PMID: 15803967.
      Citations:    
    91. Zang YC, Li S, Rivera VM, Hong J, Robinson RR, Breitbach WT, Killian J, Zhang JZ. Increased CD8+ cytotoxic T cell responses to myelin basic protein in multiple sclerosis. J Immunol. 2004 Apr 15; 172(8):5120-7. PMID: 15067096.
      Citations: 56     Fields:    Translation:HumansCells
    92. Hong J, Zang YCQ, Li S, Rivera VM, Zhang JZ. Ex vivo detection of myelin basic protein-reactive T cells in multiple sclerosis and controls using specific TCR oligonucleotide probes. Eur J Immunol. 2004 Mar; 34(3):870-881. PMID: 14991617.
      Citations: 5     Fields:    Translation:HumansCells
    93. Yang W, Keenan TP, Rozamus LW, Wang X, Rivera VM, Rollins CT, Clackson T, Holt DA. Regulation of gene expression by synthetic dimerizers with novel specificity. Bioorg Med Chem Lett. 2003 Oct 06; 13(19):3181-4. PMID: 12951089.
      Citations:    
    94. Frohman TC, Frohman EM, O'Suilleabhain P, Salter A, Dewey RB, Hogan N, Galetta S, Lee AG, Straumann D, Noseworthy J, Zee D, Corbett J, Corboy J, Rivera VM, Kramer PD. Accuracy of clinical detection of INO in MS: corroboration with quantitative infrared oculography. Neurology. 2003 Sep 23; 61(6):848-50. PMID: 14504338.
      Citations: 17     Fields:    Translation:Humans
    95. Frohman EM, Goodin DS, Calabresi PA, Corboy JR, Coyle PK, Filippi M, Frank JA, Galetta SL, Grossman RI, Hawker K, Kachuck NJ, Levin MC, Phillips JT, Racke MK, Rivera VM, Stuart WH, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. The utility of MRI in suspected MS [RETIRED]: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2003 09 09; 61(5):602-11. PMID: 12963748.
      Citations: 31     Fields:    Translation:Humans
    96. Zang YC, Hong J, Rivera VM, Killian J, Zhang JZ. Human anti-idiotypic T cells induced by TCR peptides corresponding to a common CDR3 sequence motif in myelin basic protein-reactive T cells. Int Immunol. 2003 Sep; 15(9):1073-80. PMID: 12917259.
      Citations: 5     Fields:    Translation:HumansCells
    97. Zang Y, Hong J, Robinson R, Li S, Rivera VM, Zhang JZ. Immune regulatory properties and interactions of copolymer-I and beta-interferon 1a in multiple sclerosis. J Neuroimmunol. 2003 Apr; 137(1-2):144-53. PMID: 12667659.
      Citations: 7     Fields:    Translation:HumansCells
    98. Tejada-Simon MV, Zang YC, Hong J, Rivera VM, Zhang JZ. Cross-reactivity with myelin basic protein and human herpesvirus-6 in multiple sclerosis. Ann Neurol. 2003 Feb; 53(2):189-97. PMID: 12557285.
      Citations: 95     Fields:    Translation:HumansCells
    99. Rivera VM. [Deciding on treatment in multiple sclerosis]. Rev Neurol. 2003 Jan 1-15; 36(1):80-5. PMID: 12577220.
      Citations:    Fields:    
    100. Tejada-Simon MV, Hong J, Rivera VM, Zhang JZ. Skewed autoantibody reactivity to the extracellular domain of myelin oligodendrocyte glycoprotein in multiple sclerosis. Immunology. 2002 Dec; 107(4):403-10. PMID: 12460184; PMCID: PMC1782818.
      Citations: 2     Fields:    Translation:HumansCells
    101. Tejada-Simon MV, Zang YC, Hong J, Rivera VM, Killian JM, Zhang JZ. Detection of viral DNA and immune responses to the human herpesvirus 6 101-kilodalton virion protein in patients with multiple sclerosis and in controls. J Virol. 2002 Jun; 76(12):6147-54. PMID: 12021348; PMCID: PMC136216.
      Citations: 19     Fields:    Translation:HumansCells
    102. Hong J, Tejada-Simon MV, Rivera VM, Zang YC, Zhang JZ. Anti-viral properties of interferon beta treatment in patients with multiple sclerosis. Mult Scler. 2002 May; 8(3):237-42. PMID: 12120696.
      Citations: 17     Fields:    Translation:HumansCells
    103. Zang YC, Halder JB, Hong J, Rivera VM, Zhang JZ. Regulatory effects of estriol on T cell migration and cytokine profile: inhibition of transcription factor NF-kappa B. J Neuroimmunol. 2002 Mar; 124(1-2):106-14. PMID: 11958828.
      Citations: 29     Fields:    Translation:HumansCells
    104. Zhang JZ, Rivera VM, Tejada-Simon MV, Yang D, Hong J, Li S, Haykal H, Killian J, Zang YC. T cell vaccination in multiple sclerosis: results of a preliminary study. J Neurol. 2002 Feb; 249(2):212-8. PMID: 11985389.
      Citations: 20     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    105. Rivera VM, Cabrera JA. Aboriginals with multiple sclerosis: HLA types and predominance of neuromyelitis optica. Neurology. 2001 Sep 11; 57(5):937-8. PMID: 11552042.
      Citations: 3     Fields:    Translation:Humans
    106. Tejada-Simon MV, Hong J, Rivera VM, Zhang JZ. Reactivity pattern and cytokine profile of T cells primed by myelin peptides in multiple sclerosis and healthy individuals. Eur J Immunol. 2001 Mar; 31(3):907-17. PMID: 11241296.
      Citations: 13     Fields:    Translation:HumansCells
    107. Rivera VM. [Pharmacologic treatment of multiple sclerosis]. Rev Neurol. 2001 Feb 1-15; 32(3):285-8. PMID: 11310288.
      Citations: 1     Fields:    Translation:HumansCells
    108. Ciancio SJ, Mutchnik SE, Rivera VM, Boone TB. Urodynamic pattern changes in multiple sclerosis. Urology. 2001 Feb; 57(2):239-45. PMID: 11182328.
      Citations: 25     Fields:    Translation:Humans
    109. Rivera VM. [Neuroimaging in multiple sclerosis]. Rev Neurol. 2001 Feb 1-15; 32(3):283-5. PMID: 11310287.
      Citations:    Fields:    Translation:Humans
    110. Zang YC, Halder JB, Samanta AK, Hong J, Rivera VM, Zhang JZ. Regulation of chemokine receptor CCR5 and production of RANTES and MIP-1alpha by interferon-beta. J Neuroimmunol. 2001 Jan 01; 112(1-2):174-80. PMID: 11108946.
      Citations: 15     Fields:    Translation:HumansCells
    111. Hong J, Zang YC, Tejada-Simon MV, Li S, Rivera VM, Killian J, Zhang JZ. Reactivity and regulatory properties of human anti-idiotypic antibodies induced by T cell vaccination. J Immunol. 2000 Dec 15; 165(12):6858-64. PMID: 11120809.
      Citations: 8     Fields:    Translation:HumansCellsPHPublic Health
    112. Tejada-Simon MV, Zang YC, Yang D, Hong J, Li S, Singh RA, Van den Berg-Loonen E, Killian JM, Rivera VM, Zhang JZ. Aberrant T cell responses to myelin antigens during clinical exacerbation in patients with multiple sclerosis. Int Immunol. 2000 Dec; 12(12):1641-50. PMID: 11099303.
      Citations: 7     Fields:    Translation:HumansCells
    113. Pollock R, Issner R, Zoller K, Natesan S, Rivera VM, Clackson T. Delivery of a stringent dimerizer-regulated gene expression system in a single retroviral vector. Proc Natl Acad Sci U S A. 2000 Nov 21; 97(24):13221-6. PMID: 11078518; PMCID: PMC27206.
      Citations: 28     Fields:    Translation:HumansAnimalsCells
    114. Zang YC, Samanta AK, Halder JB, Hong J, Tejada-Simon MV, Rivera VM, Zhang JZ. Aberrant T cell migration toward RANTES and MIP-1 alpha in patients with multiple sclerosis. Overexpression of chemokine receptor CCR5. Brain. 2000 Sep; 123 ( Pt 9):1874-82. PMID: 10960051.
      Citations: 26     Fields:    Translation:HumansCells
    115. Rivera VM. [The treatment of multiple sclerosis with beta-interferon 1a]. Rev Neurol. 2000 Sep 1-15; 31(5):470-1. PMID: 11027100.
      Citations:    Fields:    Translation:Humans
    116. Zang YC, Yang D, Hong J, Tejada-Simon MV, Rivera VM, Zhang JZ. Immunoregulation and blocking antibodies induced by interferon beta treatment in MS. Neurology. 2000 Aug 08; 55(3):397-404. PMID: 10932275.
      Citations: 11     Fields:    Translation:HumansCells
    117. Rollins CT, Rivera VM, Woolfson DN, Keenan T, Hatada M, Adams SE, Andrade LJ, Yaeger D, van Schravendijk MR, Holt DA, Gilman M, Clackson T. A ligand-reversible dimerization system for controlling protein-protein interactions. Proc Natl Acad Sci U S A. 2000 Jun 20; 97(13):7096-101. PMID: 10852943; PMCID: PMC16505.
      Citations: 62     Fields:    Translation:HumansCells
    118. Zang YC, Hong J, Rivera VM, Killian J, Zhang JZ. Preferential recognition of TCR hypervariable regions by human anti-idiotypic T cells induced by T cell vaccination. J Immunol. 2000 Apr 15; 164(8):4011-7. PMID: 10754292.
      Citations: 19     Fields:    Translation:HumansCellsPHPublic Health
    119. Zang YC, Hong J, Tejada-Simon MV, Li S, Rivera VM, Killian JM, Zhang JZ. Th2 immune regulation induced by T cell vaccination in patients with multiple sclerosis. Eur J Immunol. 2000 Mar; 30(3):908-13. PMID: 10741408.
      Citations: 12     Fields:    Translation:HumansCellsPHPublic Health
    120. Rivera VM, Wang X, Wardwell S, Courage NL, Volchuk A, Keenan T, Holt DA, Gilman M, Orci L, Cerasoli F, Rothman JE, Clackson T. Regulation of protein secretion through controlled aggregation in the endoplasmic reticulum. Science. 2000 Feb 04; 287(5454):826-30. PMID: 10657290.
      Citations: 121     Fields:    Translation:HumansAnimalsCells
    121. Singh RA, Zang YC, Shrivastava A, Hong J, Wang GT, Li S, Tejada-Simon MV, Kozovska M, Rivera VM, Zhang JZ. Th1 and Th2 deviation of myelin-autoreactive T cells by altered peptide ligands is associated with reciprocal regulation of Lck, Fyn, and ZAP-70. J Immunol. 1999 Dec 15; 163(12):6393-402. PMID: 10586029.
      Citations: 3     Fields:    Translation:HumansCells
    122. Natesan S, Molinari E, Rivera VM, Rickles RJ, Gilman M. A general strategy to enhance the potency of chimeric transcriptional activators. Proc Natl Acad Sci U S A. 1999 Nov 23; 96(24):13898-903. PMID: 10570170; PMCID: PMC24162.
      Citations: 3     Fields:    Translation:HumansCells
    123. Kozovska ME, Hong J, Zang YC, Li S, Rivera VM, Killian JM, Zhang JZ. Interferon beta induces T-helper 2 immune deviation in MS. Neurology. 1999 Nov 10; 53(8):1692-7. PMID: 10563614.
      Citations: 27     Fields:    Translation:HumansCells
    124. Hong J, Zang YC, Tejada-Simon MV, Kozovska M, Li S, Singh RA, Yang D, Rivera VM, Killian JK, Zhang JZ. A common TCR V-D-J sequence in V beta 13.1 T cells recognizing an immunodominant peptide of myelin basic protein in multiple sclerosis. J Immunol. 1999 Sep 15; 163(6):3530-8. PMID: 10477628.
      Citations: 15     Fields:    Translation:HumansCells
    125. Kil K, Zang YC, Yang D, Markowski J, Fuoco GS, Vendetti GC, Rivera VM, Zhang JZ. T cell responses to myelin basic protein in patients with spinal cord injury and multiple sclerosis. J Neuroimmunol. 1999 Aug 03; 98(2):201-7. PMID: 10430053.
      Citations: 37     Fields:    Translation:HumansCells
    126. Rivera VM, Ye X, Courage NL, Sachar J, Cerasoli F, Wilson JM, Gilman M. Long-term regulated expression of growth hormone in mice after intramuscular gene transfer. Proc Natl Acad Sci U S A. 1999 Jul 20; 96(15):8657-62. PMID: 10411931; PMCID: PMC17572.
      Citations: 29     Fields:    Translation:HumansAnimalsCells
    127. Zang YC, Kozovska MM, Hong J, Li S, Mann S, Killian JM, Rivera VM, Zhang JZ. Impaired apoptotic deletion of myelin basic protein-reactive T cells in patients with multiple sclerosis. Eur J Immunol. 1999 05; 29(5):1692-700. PMID: 10359124.
      Citations: 11     Fields:    Translation:HumansCells
    128. Pollock R, Rivera VM. Regulation of gene expression with synthetic dimerizers. Methods Enzymol. 1999; 306:263-81. PMID: 10432459.
      Citations: 4     Fields:    Translation:HumansCells
    129. Keenan T, Yaeger DR, Courage NL, Rollins CT, Pavone ME, Rivera VM, Yang W, Guo T, Amara JF, Clackson T, Gilman M, Holt DA. Synthesis and activity of bivalent FKBP12 ligands for the regulated dimerization of proteins. Bioorg Med Chem. 1998 Aug; 6(8):1309-35. PMID: 9784872.
      Citations: 15     Fields:    Translation:HumansCells
    130. Zang YC, Kozovska M, Aebischer I, Li S, Boehme S, Crowe P, Rivera VM, Zhang JZ. Restricted TCR Valpha gene rearrangements in T cells recognizing an immunodominant peptide of myelin basic protein in DR2 patients with multiple sclerosis. Int Immunol. 1998 Jul; 10(7):991-8. PMID: 9701037.
      Citations: 1     Fields:    Translation:HumansCells
    131. Kozovska M, Zang YC, Aebischer I, Lnu S, Rivera VM, Crowe PD, Boehme SA, Zhang JZ. T cell recognition motifs of an immunodominant peptide of myelin basic protein in patients with multiple sclerosis: structural requirements and clinical implications. Eur J Immunol. 1998 Jun; 28(6):1894-901. PMID: 9645371.
      Citations: 5     Fields:    Translation:HumansCells
    132. Kim YH, Goodman C, Omessi E, Rivera V, Kattan MW, Boone TB. The correlation of urodynamic findings with cranial magnetic resonance imaging findings in multiple sclerosis. J Urol. 1998 Mar; 159(3):972-6. PMID: 9474196.
      Citations: 12     Fields:    Translation:Humans
    133. Amara JF, Clackson T, Rivera VM, Guo T, Keenan T, Natesan S, Pollock R, Yang W, Courage NL, Holt DA, Gilman M. A versatile synthetic dimerizer for the regulation of protein-protein interactions. Proc Natl Acad Sci U S A. 1997 Sep 30; 94(20):10618-23. PMID: 9380684; PMCID: PMC23423.
      Citations: 58     Fields:    Translation:HumansCells
    134. Jerger J, Alford B, Lew H, Rivera V, Chmiel R. Dichotic listening, event-related potentials, and interhemispheric transfer in the elderly. Ear Hear. 1995 Oct; 16(5):482-98. PMID: 8654903.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    135. Rivera VM, Brugge JS. Clustering of Syk is sufficient to induce tyrosine phosphorylation and release of allergic mediators from rat basophilic leukemia cells. Mol Cell Biol. 1995 Mar; 15(3):1582-90. PMID: 7532280; PMCID: PMC230382.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    136. Safi HJ, Bartoli S, Hess KR, Shenaq SS, Viets JR, Butt GR, Sheinbaum R, Doerr HK, Maulsby R, Rivera VM. Neurologic deficit in patients at high risk with thoracoabdominal aortic aneurysms: the role of cerebral spinal fluid drainage and distal aortic perfusion. J Vasc Surg. 1994 Sep; 20(3):434-44; discussion 442-3. PMID: 8084037.
      Citations: 14     Fields:    Translation:Humans
    137. Crawford ES, Svensson LG, Hess KR, Shenaq SS, Coselli JS, Safi HJ, Mohindra PK, Rivera V. A prospective randomized study of cerebrospinal fluid drainage to prevent paraplegia after high-risk surgery on the thoracoabdominal aorta. J Vasc Surg. 1991 Jan; 13(1):36-45; discussion 45-6. PMID: 1987395.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    138. Mawad ME, Rivera V, Crawford S, Ramirez A, Breitbach W. Spinal cord ischemia after resection of thoracoabdominal aortic aneurysms: MR findings in 24 patients. AJR Am J Roentgenol. 1990 Dec; 155(6):1303-7. PMID: 2122684.
      Citations: 13     Fields:    Translation:Humans
    139. Mawad ME, Rivera V, Crawford S, Ramirez A, Breitbach W. Spinal cord ischemia after resection of thoracoabdominal aortic aneurysms: MR findings in 24 patients. AJNR Am J Neuroradiol. 1990 Sep-Oct; 11(5):987-91. PMID: 2121005; PMCID: PMC8334116.
      Citations: 15     Fields:    Translation:Humans
    140. Rivera VM. Multiple sclerosis. Is the mystery beginning to unfold? Postgrad Med. 1986 Jun; 79(8):217-32. PMID: 3520524.
      Citations: 1     Fields:    Translation:HumansCells
    141. Rivera VM, Meyer JS, Hata T, Ishikawa Y, Imai A. Narcolepsy following cerebral hypoxic ischemia. Ann Neurol. 1986 May; 19(5):505-8. PMID: 3717910.
      Citations: 5     Fields:    Translation:Humans
    142. Hannley M, Jerger JF, Rivera VM. Relationships among auditory brain stem responses, masking level differences and the acoustic reflex in multiple sclerosis. Audiology. 1983; 22(1):20-33. PMID: 6830528.
      Citations: 2     Fields:    Translation:Humans
    143. Rivera VM. Intraspinal steroid therapy. Neurology. 1981 Aug; 31(8):1060-1. PMID: 6894967.
      Citations: 1     Fields:    Translation:Humans
    144. Rivera VM, Grabois M, Deaton W, Breitbach W, Hines M. Modified snake venom in amyotrophic lateral sclerosis. Lack of clinical effectiveness. Arch Neurol. 1980 Apr; 37(4):201-3. PMID: 7362484.
      Citations: 3     Fields:    Translation:Humans
    145. Jankovic J, Rivera VM. Hereditary myoclonus and progressive distal muscular atrophy. Ann Neurol. 1979 Sep; 6(3):227-31. PMID: 534421.
      Citations: 11     Fields:    Translation:Humans
    RIVERA's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (627)
    Explore
    _
    Co-Authors (4)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _